 Protein-Tyrosine Kinases
"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
| Descriptor ID |
D011505
|
| MeSH Number(s) |
D08.811.913.696.620.682.725
|
| Concept/Terms |
Protein-Tyrosine Kinases- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 4 | 3 | 7 | | 1992 | 4 | 0 | 4 | | 1993 | 9 | 2 | 11 | | 1994 | 8 | 4 | 12 | | 1995 | 8 | 5 | 13 | | 1996 | 5 | 3 | 8 | | 1997 | 10 | 9 | 19 | | 1998 | 8 | 11 | 19 | | 1999 | 5 | 11 | 16 | | 2000 | 4 | 7 | 11 | | 2001 | 6 | 8 | 14 | | 2002 | 9 | 8 | 17 | | 2003 | 13 | 5 | 18 | | 2004 | 6 | 2 | 8 | | 2005 | 5 | 0 | 5 | | 2006 | 5 | 4 | 9 | | 2007 | 7 | 6 | 13 | | 2008 | 5 | 5 | 10 | | 2009 | 6 | 4 | 10 | | 2010 | 5 | 2 | 7 | | 2011 | 4 | 2 | 6 | | 2012 | 8 | 3 | 11 | | 2013 | 10 | 6 | 16 | | 2014 | 10 | 4 | 14 | | 2015 | 6 | 3 | 9 | | 2016 | 7 | 2 | 9 | | 2017 | 6 | 3 | 9 | | 2018 | 12 | 3 | 15 | | 2019 | 9 | 2 | 11 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.
-
Rizzo AN, Belvitch P, Demeritte R, Garcia JGN, Letsiou E, Dudek SM. Arg mediates LPS-induced disruption of the pulmonary endothelial barrier. Vascul Pharmacol. 2020 May - Jun; 128-129:106677.
-
Haltenhof T, Kotte A, De Bortoli F, Schiefer S, Meinke S, Emmerichs AK, Petermann KK, Timmermann B, Imhof P, Franz A, Loll B, Wahl MC, Preußner M, Heyd F. A Conserved Kinase-Based Body-Temperature Sensor Globally Controls Alternative Splicing and Gene Expression. Mol Cell. 2020 04 02; 78(1):57-69.e4.
-
Cho HS, Ha S, Shin HM, Reboldi A, Hall JA, Huh JR, Usherwood EJ, Berg LJ. CD8+ T Cells Require ITK-Mediated TCR Signaling for Migration to the Intestine. Immunohorizons. 2020 02 07; 4(2):57-71.
-
Gilani A, Donson A, Davies KD, Whiteway SL, Lake J, DeSisto J, Hoffman L, Foreman NK, Kleinschmidt-DeMasters BK, Green AL. Targetable molecular alterations in congenital glioblastoma. J Neurooncol. 2020 Jan; 146(2):247-252.
-
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609.
-
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):261-270.
-
Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
-
Patil T, Camidge DR. Untapped potential: recognising CNS opportunities in early oncology drug development. Lancet Oncol. 2019 12; 20(12):1620-1622.
-
Leach SM, Finigan J, Vasu VT, Mishra R, Ghosh M, Foster D, Mason R, Kosmider B, Farias Hesson E, Kern JA. The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer. Am J Respir Cell Mol Biol. 2019 10; 61(4):481-491.
-
Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct; 55(10):641-652.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|